New Finding Underscores Importance Of Controlling Opportunistic Infection

June 19, 1997

One of the many questions surrounding AIDS has been where HIV comes from in the latter stages of the disease, when the patients have low CD4 T cell counts. A report in the June 20 issue of Science identifies a source as tissue macrophages, and points to opportunistic infections as a trigger that sets off a wave of HIV production.

This finding has several important implications, according to investigators Dr. Jan Orenstein from George Washington University and Dr. Sharon Wahl from the National Institute of Dental Research. "Preventing or eliminating opportunistic infections is not only essential to the immediate well-being of the patient, but can also slow the cycle of virus production that leads to further immune system damage," said Dr. Wahl. "The macrophage appears to be a key player in this scenario by functioning as a long-lived reservoir of virus production. " It has been known for some time that CD4 T cells are the primary target of HIV infection, and that their destruction leads to a weakened immune system and susceptibility to "opportunists"--microorganisms that normally don't infect a healthy individual. As HIV infection progresses toward AIDS, the CD4 T cells are the chief source of new virus, creating a cycle of escalating virus production and T cell death. The paradox has been how the levels of HIV continue to increase over the course of AIDS, at the same time the T cell population dramatically decreases.

Drs. Orenstein and Wahl thought macrophages might hold the answer to this riddle. Macrophages are immune cells that roam throughout the tissues for periods from months to perhaps years, seeking out and destroying invading organisms. The scientists knew that macrophages could be infected with HIV, but these voracious scavengers were not thought to be a significant source of virus production.

Close examination of lymph nodes from AIDS patients infected with a variety of common opportunists, including Pneumocystis carinii and Mycobacterium avium, proved otherwise. These patients not only had from 5 to over 100 times the number of virus-producing macrophages found in the nodes of opportunist-free HIV patients, the individual macrophages also demonstrated a much higher level of virus production.

The actual mechanism that switches macrophages from HIV carriers to producers is not yet known. Opportunistic microorganisms apparently act as a magnet, say the investigators, pulling together large numbers of both HIV-infected and uninfected macrophages. The opportunists then in some way stimulate the HIV-infected macrophages to produce virus, which ultimately spreads to uninfected macrophages and T cells.

The members of the research team were Dr. Jan Orenstein, George Washington University, Washington, DC; Dr. Cecil Fox, Molecular Histology, Inc., Gaithersburg, MD; and Dr. Sharon Wahl, National Institute of Dental Research, National Institutes of Health, Bethesda, MD

NIH/National Institute of Dental and Craniofacial Research

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to